SEARCH:   Advanced

This Article Abstract Full Text (PDF) Erratum (v95,p3010) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Panzer-Grümayer, E. R. Articles by Gadner, H. Search for Related Content PubMed PubMed Citation Articles by Panzer-Grümayer, E. R. Articles by Gadner, H. Related Collections Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 3 (February 1), 2000: pp. 790-794 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia E. Renate Panzer-Grümayer, Monika Schneider, Simon Panzer, Karin Fasching, and Helmut Gadner From the Children's Cancer Research Institute and St. Anna Kinderspital, and the Institute of Blood Group Serology, University of Vienna, Vienna, Austria.     Abstract Top Abstract Introduction Patients and methods Results Discussion References Early response to therapy is an independent prognostic factor in childhood acute lymphoblastic leukemia. Although most patients have rapid early responses, as detected by morphology, 15% to 20% of patients have relapses. The authors evaluated residual disease by molecular methods on day 15 of minimal residual disease (MRD) therapy and compared these data with their recently established MRD-based risk stratification, defined by MRD levels 5 weeks after induction treatment and before consolidation. All 68 children treated according to current Berlin-Frankfurt-Münster (BFM) protocols went into morphologically complete remission after induction. There was a significant difference in outcome between children with rapid disease clearance and those with high levels of day-15 MRD (P = .035). Among patients with high levels of day-15 MRD, only the MRD-based risk stratification was predictive of the outcome. All patients with negative or low day-15 MRD had excellent prognoses and were in the MRD-based low-risk group. Thus, after only 2 weeks of treatment, the authors were able to identify a patient population of 20% who may benefit from the least intensive treatment. (Blood. 2000;95:790-794) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients and methods Results Discussion References Current treatment strategies use clinical and biologic features at the time of diagnosis for risk-adapted therapy in childhood acute lymphoblastic leukemia (ALL), resulting in overall relapse-free survival rates of approximately 75%.1 Early response to chemotherapy was found to add to the definition of a patient's individual risk.2 Early response has been measured by morphologic evaluation of blasts in peripheral blood after 1 week of prednisone therapy and of multiagent chemotherapy.3,4 An adverse prognosis was preceded by a slow response. However, even 20% of patients with rapid early responses to either of those treatments undergo relapse.3,4 In another approach, bone marrow rating after 1 or 2 weeks of therapy was investigated for its predictive value. Again, patients with high blast cell counts were at higher risk for relapse than were patients with counts smaller than 5%. Relapses, however, primarily occur in the latter group, to which most patients belong.2 Molecular evaluation has shown that the amount of residual disease a patient has at the time of conventional morphologic remission and after treatment with induction chemotherapy is of prognostic significance.5-8 By using 2 time pointsafter 5 weeks of induction chemotherapy and before consolidationwe identified 3 MRD-based risk groups.8 We previously observed that some patients undergo very rapid clearance of residual disease, as evaluated by antigen-receptor gene rearrangements (E.R.P.-G., unpublished data). Therefore, we sought to gain information in a larger group of patients on the relationship between residual disease detected by morphologic marrow rating and molecular analysis on day-15 MRD with the MRD-based risk groups. We hypothesized that by day-15 MRD, a subgroup of patients with less than 5% blasts in the bone marrow on day 15 could be identified as part of the MRD-based low-risk group.     Patients and methods Top Abstract Introduction Patients and methods Results Discussion References Patient selection Sixty-eight children with ALL treated according to current BFM protocols (ALL-BFM 90 and 95) were included in this study. The patients were selected on the availability of day 15 marrow samples for morphologic and molecular analysis and of bone marrow cells during follow-up for MRD analysis. Clinical characteristics of the patients did not deviate from those of the additional 223 children enrolled in the MRD studies in Austria between January 1, 1992 and April 30, 1997 regarding age, sex, white blood cell count, immunophenotype of the leukemia, prednisone response, distribution among BFM risk groups, and incidence and site of relapse (Table 1; P > .1). Of these 68 children, 33 were girls and 35 were boys. Age at diagnosis ranged from 2 months to 17 years (median, 4.4 years). The diagnosis of ALL was based on standard morphologic criteria and cytochemical staining of leukemia cells. Immunophenotyping of the leukemia cells was performed according to standard procedures, and it revealed B-lineage type leukemia in 58 children (3 pre-pre-B ALL, 45 common ALL, 10 pre-B ALL) and T-lineage phenotype leukemia in 10 children (4 early T-ALL, 5 intermediate T-ALL, 1 late T-ALL). Cytogenetic analysis was performed in all children; t(4;11) and t(9;22) were identified in 3 and 2 children, respectively.                                View this table: [in this window] [in a new window]   Table 1. Clinical characteristics of 68 patients with ALL at diagnosis Criteria for inclusion in this study were morphologic and molecular evaluations of bone marrow day 15 and MRD analyses after induction and before consolidation treatment. Only patients with representative day 15 bone marrow smears, including autochthonous bone marrow structures, were included. Each institution's ethics committee approved the study design, and informed consent was obtained from the patients or their parents. Treatment protocol ALL-BFM 90 and 95 study designs, treatment regimens, and preliminary results have been published elsewhere.9 In brief, patients were stratified according to the 3 groupsthe standard-risk group (SRG), the medium-risk group (MRG), and the high-risk group (HRG)on the basis of risk factor 1) (risk factor was substituted in the BFM-ALL 95 study by age at diagnosis and initial WBC count, 2) prednisone response in peripheral blood, 3) translocation t(9;22) and t(4;11) in the BFM- ALL 95 study, 4) by initial central nervous system disease, and 5) blast-cell immunophenotype. Induction treatment (protocol 1) started with 1 week of prednisone and intrathecal methotrexate (protocol 1/phase 1) and continued with a 5-drug regimen over a period of 4 weeks with daily prednisone, intrathecal methotrexate on days 15 and 29, weekly vincristine and daunorubicin, and 3×/week l-asparaginase. Further therapy (protocol 1/phase 2) for SRG and MRG patients consisted of daily 6-mercaptopurine for 4 weeks, cyclophosphamide on days 36 and 64, cytosine arabinoside (ARA-C) 4×/week, and intrathecal methotrexate on days 45 and 59. The following consolidation treatment (protocol M) consisted of an 8-week course of 6-mercaptopurine, high-dose methotrexate, and intrathecal methotrexate. For HRG patients induction therapy was followed by intensive consolidation therapy with 9 (6 in BFM-ALL 95 protocol plus protocol 2) 6-day cycles containing combinations of dexamethasone, vincristine/vindesine, 6-thioguanine/6-mecaptopurine, ifosfamide, etoposide, intrathecal methotrexate/ARA-C/PRED and HD-methotrexate, or HD-ARA-C. Prophylactic cranial irradiation was applied after intensive consolidation. Most patients underwent maintenance chemotherapy for a total treatment duration of 24 months; SRG boys in the BFM-ALL 95 protocol underwent chemotherapy for 36 months. The local institutional review boards approved the study design, and informed consent of the parents was obtained. Evaluation of response to chemotherapy Bone marrow smears by light microscopy. Bone marrow aspirates were analyzed by cytomorphologic criteria and were rated M1, M2, and M3 based on the percentage of blasts (less than 5%, 5% to 25%, and more than 25%, respectively). The rating was performed centrally. Bone marrow mononuclear cells by MRD analysis. After the identification of leukemia clone-specific antigen receptor gene rearrangements (IgH, Ig, TCRD, TCRG) in DNA from diagnostic bone marrow using single or multiplex polymerase chain reaction (PCR) as described previously,10-12 junctional region-specific oligonucleotides were designed. The oligonucleotides were then used for dot blot hybridization of PCR-amplified DNA from follow-up samples.8,12,13 The amount of residual leukemia was estimated by comparing the signal of the follow-up sample with a log dilution of bone marrow cells from diagnosis. High tumor loads corresponding to greater than 102 were summarized as greater than or equal to 102. MRD results of 105 were clustered with the 104 results. A sensitivity of at least 104 of 1 target was required for inclusion in this study. In accordance with our previous study,8 we used MRD levels of greater than or equal to 102, 103, and less than or equal to 104 for the day 15 evaluations. Classifying the children into 3 different MRD-based risk groups was based on the combined information of MRD levels after induction protocol 1/phase1 (time point 1) and before the start of consolidation 2 weeks after the end of protocol 1/phase 2 (time point 2), as follows: low risk (LR), MRD negative at time point 1; intermediate risk (IR), < 103 at time point 2; high risk (HR), persistent high tumor loads greater than or equal to 103 at time point 2.8 Statistical analysis For univariate analysis, the log-rank test14 was used to explore prognostic impact on relapse-free survival of day-15 marrow response and MRD-based risk group stratification. Life-table estimates of relapse-free survival (RFS) at 5 years were derived by the method of Kaplan and Meier15 and were compared using the stratified log-rank test. The influence of potential prognostic factors on RFS was estimated with the Cox proportional hazard model.16 The factors tested included BFM risk group stratification (SRG, MRG, and HRG), marrow rating on day 15, day-15 MRD levels (MRD less than or equal to 104, 103, and greater than or equal to 102), and MRD-based risk groups (MRD-LR, MRD-IR, and MRD-HR).4 Each factor was first tested as a single variable in the Cox regression model (univariate analysis). The significance of these variables was then tested in a multivariate analysis after removing each from the model that has all 4 factors included.     Results Top Abstract Introduction Patients and methods Results Discussion References Clinical course of the disease Based on their symptoms and their responses to prednisone therapy, children were stratified for treatment according to BFM risk groups (Table 1). Sixteen children were in SRG, 40 were in MRG, and 12 were in HRG (Tables 1 and 2). All 68 children enrolled in this study went into morphologic remission after induction chemotherapy. Currently, the median observation time is 5 years 6 months (range, 1 year 7 months to 8 years 11 months). Sixteen patients had relapses. Fourteen patients had isolated relapses in the bone marrow; 1 was in the SRG, 6 were in the MRG, and 7 were in the HRG. One SRG patient suffered a combined central nervous system/bone marrow relapse and 1 HRG patient had an isolated relapse in the testis. The probability for RFS at 5 years for SRG, MRG, and HRG was 88.8%, 84.6%, and 28.14%, respectively. Log-rank tests for BFM risk group stratification showed no differences between SRG and MRG in RFS but a significant difference in RFS between these 2 groups and HRG (P < .001, Figure 1). Relative risk for relapse of HRG and MRG patients compared with SRG patients was 8.9 (95% CI, 1.8-42.4) and 1.2 (95% CI, 0.3-6.1), respectively, and of HRG patients compared with MRG patients it was 7.2 (95% CI, 2.5-20.8).                                View this table: [in this window] [in a new window]   Table 2. Comparison of day-15 marrow rating, day-15 MRD, and MRD-based risk groups with BFM risk groups View larger version (17K): [in this window] [in a new window]   Fig 1. Probability of RFS in children with B and T lineage ALL according to BFM risk group stratification. Day-15 marrow blasts and day-15 MRD analysis Overall, and in line with previous reports,2 the predictive value of marrow rating on day 15 on RFS was significant (P < .001, Figure 2). A higher rating (M2 and M3) was associated with an increased incidence of relapse. However, even an M1 rating was found in patients who later had relapses (Table 2). The relative risk for relapse of patients with M3 and M2 compared to M1 was 12.8 (95% CI, 3.8-43.2) and 2.0 (95% CI, 0.5-7.9), respectively, and of patients with M3 compared to M2 it was 6.5 (95% CI, 3.8-21.7). As was already assumed from the BFM risk group stratification, a higher rating was seen in HRG patients. No patient in the BFM HRG had an M1 rating, whereas several had M3 ratings. Although M2 and M3 ratings did not discriminate between children in the BFM HRG who had relapses and those who remained in continuous complete remission, day-15 M3 morphology was a prognostic parameter in the remaining patients. The trend for day-15 marrow rating as a prognostic factor occurred only after BFM risk group stratification (P = .072). View larger version (16K): [in this window] [in a new window]   Fig 2. Probability of RFS according to morphologic bone marrow rating on day 15. In accordance with the MRD levels in our previous study,8 we used MRD loads of greater than or equal to102, 103, and less than or equal to104. There was a significant difference between patients with tumor loads of greater than or equal to 102 and those with less than or equal to 104 (P = .014), and a trend between patients with MRD levels of less than or equal to 104 and 103 (P = .096; Table 2, Figure 3). The levels allowed discrimination among 3 groups of patients1 group in which all children remained in continuous complete remission (day-15 MRD less than or equal to 104) and 2 in which children went into relapse (day-15 MRD 103 and greater than or equal to 102) (Table 2, Figure 3). Day-15 MRD levels of 103 and greater than or equal to 102 were found in patients who remained in continuous complete remission as well as in patients who had relapses. In 37 patients with M1 marrow, day-15 MRD levels were less than or equal to 102, and in 31 children with M2 or M3 ratings, day-15 MRD levels were greater than or equal to 102. We used Cox regression analysis to determine whether day-15 MRD data added to the information gained by the BFM risk group stratification. Day-15 MRD and BFM stratification were significant prognostic factors (P < .023). View larger version (15K): [in this window] [in a new window]   Fig 3. Probability of RFS according to day-15 MRD levels. MRD-based risk group stratification There was no relapse in the MRD-based LR group, but relapses in the IR and HR groups were 33% and 88%, respectively (Table 2, Figure 4). There was a significant difference for the probability of RFS in the 3 groups at 5 years (P < .001). Approximately 50% of patients in the BFM SRG and MRG were in the MRD-based LR group (Table 2). View larger version (15K): [in this window] [in a new window]   Fig 4. Probability of RFS according to MRD-based risk group stratification. Comparison between BFM risk groups, morphologic and molecular analysis on day 15, and MRD-based risk group stratification All 14 patients with low (less than or equal to 104) or undetectable levels of day-15 MRD were in the MRD-based LR group. Seventeen patients had high tumor loads (greater than or equal to 103) on day 15 but subsequently achieved MRD-based LR criteria. Twenty-nine patients with high day-15 MRD levels were in the MRD-based IR group, and 9 of them had relapses. Eight children had high day-15 MRD levels and retained MRD-based HR criteria; 7 had relapses. We used Cox regression analysis to test the significance for each of the factors (BFM risk group, day-15 marrow rating, day-15 MRD, MRD-based risk group). The MRD-based risk group stratification was the only independent prognostic factor for outcome (P < .001). Although day-15 MRD was not significant in this model, low levels of day-15 MRD (less than or equal to 104) identified a group of patients with very rapid responses to therapy who had good outcomes. Their low risk was substantiated by the MRD-based LR group assignment, which was based on MRD levels obtained at later time points.     Discussion Top Abstract Introduction Patients and methods Results Discussion References By analyzing MRD in bone marrow on day 15, we were able to identify a group of patients who responded rapidly to chemotherapy and had excellent prognoses. This prediction of a good outcome was substantiated by the findings that these patients belonged to the MRD-based low-risk group, which was based on MRD levels at later time points. Currently, approximately 30% of patients who will have relapses of leukemia can be identified by clinical and biologic features at diagnosis.1 Early response to therapy is of additional importance.2 In the past, early response to chemotherapy was evaluated by morphology. It is recognized that approximately10% of all patients have more than 25% blasts in the bone marrow after 2 weeks of chemotherapy and that they are at increased risk for relapse.2 It is also recognized that relapses even occur in patients with good early responses (M1) and favorable features at diagnosis.17 Moreover, according to Children's Cancer Group (CCG) studies, more than 20% of patients at higher risk have relapses despite rapid early responses.18,19 In line with these data, we observed that 10% of patients in BFM MRG had relapses even though they had M1 marrow at day 15. We therefore hypothesized that by day-15 MRD, differentiation could be made between patients who would remain in complete remission and those who would have relapses. Approximately 20% of patients with less than 5% blasts in the bone marrow had low (less than or equal to 104) or undetectable amounts of day-15 MRD and did not have relapses. When the results from the MRD-based risk group stratification became available, these patients were in the MRD-based low risk group, confirming their excellent prognoses. Thus, we identified by day-15 MRD analysis a subgroup of patients with favorable prognoses who may comprise the target population for the least intensive form of chemotherapy. By life table estimates, patients with MRD levels of less than or equal to 104 had RFS probability levels of 100% projected at 5 years. One patient, however, had an observation time of < 3.5 years. This was the latest time point at which a patient with MRD levels of greater than or equal to 103 had a relapse. All relapses occurred in patients with MRD levels of greater than or equal to 103. There was no difference regarding risk for a relapse whether the day-15 MRD level was greater than or equal to 102 or 103. Therefore, those high MRD levels did not predict risk for relapse. For these patients only the MRD-based risk groups, as defined at later time points, were predictive. Prednisone response, measured by the number of persistent blasts in the peripheral blood on day 8, has been used for treatment stratification in BFM protocols since 1986.9 Therefore, we appointed prednisone-poor responders to the BFM HRG. Day-15 M3 marrow, found in 67% of our BFM HRG patients, did not provide additional prognostic information. In contrast, day-15 M3 marrow indicated a poor prognosis for the patient with a good response to prednisone. Similar observations in a larger group of patients have been reported.3,9 However, according to MRD-based risk group, patients with day-15 M3 marrow can be differentiated into those who will remain in complete remission and those who will have relapses. Thus, MRD-based risk groups abolish the prognostic impact of day-15 morphology. This finding is of particular interest because in the next treatment protocol we will stratify patients according to the recently established MRD-based risk groups, prognostic factors at diagnosis, and prednisone responses. In conclusion, with low levels of day-15 MRD, we were able to identify patients with rapid molecular responses to therapy. These patients were derived from groups with good responses to prednisone therapy and those with rapid morphological responses on day 15. They comprised half the patients in the MRD-based low-risk group and were the most likely to be cured with the least intenive therapy.     Acknowledgments We thank S. Fischer and R. Kornmüller for excellent technical assistance, U. Pötschger for statistical analysis, and O. A. Haas for providing the data on day-15 marrow rating and cytogenetic analysis. We also thank Drs B. Ausserer, F. M. Fink, R. Jones, G. Mann, G. Müller, I. Mutz, R. Ployer, N. Pobegen, K. Schmitt, and O. Stöllinger for providing bone marrow samples.     Footnotes Submitted April 23, 1999; accepted September 27, 1999. Supported in part by the Österreichische Kinderkrebshilfe and by private donations to the Children's Cancer Research Institute. Reprints: E. Renate Panzer-Grümayer, Children's Cancer Research Institute/St. Anna Kinderspital, Kinderspitalg, 6 A-1090 Vienna, Austria; e-mail: panzer{at}ccri.univie.ac.at. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Patients and methods Results Discussion References 1. Pui C-H. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 1998;5:292[Medline] [Order article via Infotrieve]. 2. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80:1717[Medline] [Order article via Infotrieve]. 3. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2403[Medline] [Order article via Infotrieve]. 4. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after one week of multi agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292[Abstract/Free Full Text]. 5. Wassermann R, Galili N, Ito JH, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol. 1992;10:1879[Abstract]. 6. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet. 1994;343:196[Medline] [Order article via Infotrieve]. 7. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339:591[Abstract/Free Full Text]. 8. Van Dongen JM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731[Medline] [Order article via Infotrieve]. 9. Schrappe M, Reiter A, Sauter S, et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark [German]. Klin Pädiatr. 1994;206:208[Medline] [Order article via Infotrieve]. 10. Hettinger K, Fischer S, Panzer S, Panzer-Grümayer ER. Multiplex PCR for TCR delta rearrangements: a rapid and specific approach for the detection and identification of immature and mature rearrangements in ALL. Br J Haematol. 1998;102:1050[Medline] [Order article via Infotrieve]. 11. Stolz F, Panzer S, Fischer S, Panzer-Grümayer ER. Oligoclonal IgH and TCR rearrangements persist in a recurrent ALL with one Ig rearrangement as a clonal marker. Mod Pathol. 1999;12:819[Medline] [Order article via Infotrieve]. 12. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the Biomed-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:110[Medline] [Order article via Infotrieve]. 13. Ghali DW, Panzer S, Fischer S, et al. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias. Blood. 1995;85:2795[Abstract/Free Full Text]. 14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1958;22:719. 15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn. 1958;53:457. 16. Cox D. Regression models and live tables. J R Stat Soc (B). 1972;34:187. 17. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol. 1989;7:1807[Abstract]. 18. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990;18:273[Medline] [Order article via Infotrieve]. 19. Nachman J, Sather H, Lukens J, et al. Intrathecal methotrexate is sufficient central nervous (CNS) prophylaxis for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid early response (RER) to BFM induction chemotherapy. Blood. 1995;86(suppl):265a. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse Valerie de Haas, Willemyn B. Breunis, Onno J. Verhagen, Henk van den Berg, and C. Ellen van der Schoot Blood 2000 96: 1619-1620. [Full Text] [PDF] This article has been cited by other articles: C. A. Scrideli, J. G. Assumpcao, M. A. Ganazza, M. Araujo, S. R. Toledo, M. L. M. Lee, E. Delbuono, A. S. Petrilli, R. P. Queiroz, A. Biondi, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups Haematologica, June 1, 2009; 94(6): 781 - 789. [Abstract] [Full Text] [PDF] J. Irving, J. Jesson, P. Virgo, M. Case, L. Minto, L. Eyre, N. Noel, U. Johansson, M. Macey, L. Knotts, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting; Haematologica, June 1, 2009; 94(6): 870 - 874. [Abstract] [Full Text] [PDF] M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood, June 15, 2008; 111(12): 5477 - 5485. [Abstract] [Full Text] [PDF] J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood, September 1, 2007; 110(5): 1607 - 1611. [Abstract] [Full Text] [PDF] C. Flotho, E. Coustan-Smith, D. Pei, C. Cheng, G. Song, C.-H. Pui, J. R. Downing, and D. Campana A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia Blood, August 15, 2007; 110(4): 1271 - 1277. [Abstract] [Full Text] [PDF] C. Flotho, E. Coustan-Smith, D. Pei, S. Iwamoto, G. Song, C. Cheng, C.-H. Pui, J. R. Downing, and D. Campana Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2 Blood, August 1, 2006; 108(3): 1050 - 1057. [Abstract] [Full Text] [PDF] E. Coustan-Smith, R. C. Ribeiro, P. Stow, Y. Zhou, C.-H. Pui, G. K. Rivera, F. Pedrosa, and D. Campana A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Blood, July 1, 2006; 108(1): 97 - 102. [Abstract] [Full Text] [PDF] M. Bruggemann, T. Raff, T. Flohr, N. Gokbuget, M. Nakao, J. Droese, S. Luschen, C. Pott, M. Ritgen, U. Scheuring, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood, February 1, 2006; 107(3): 1116 - 1123. [Abstract] [Full Text] [PDF] S. Schnittger, M. Weisser, C. Schoch, W. Hiddemann, T. Haferlach, and W. Kern New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts Blood, October 15, 2003; 102(8): 2746 - 2755. [Abstract] [Full Text] [PDF] M.-B. Vidriales, J. J. Perez, M. C. Lopez-Berges, N. Gutierrez, J. Ciudad, P. Lucio, L. Vazquez, R. Garcia-Sanz, M. C. del Canizo, J. Fernandez-Calvo, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood, June 15, 2003; 101(12): 4695 - 4700. [Abstract] [Full Text] [PDF] J Moppett, G A A Burke, C G Steward, A Oakhill, and N J Goulden The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia J. Clin. Pathol., April 1, 2003; 56(4): 249 - 253. [Abstract] [Full Text] [PDF] W. Kern, T. Haferlach, C. Schoch, H. Loffler, W. Gassmann, A. Heinecke, M. C. Sauerland, W. Berdel, T. Buchner, and W. Hiddemann Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood, January 1, 2003; 101(1): 64 - 70. [Abstract] [Full Text] [PDF] L. Trumper, M. Menges, H. Daus, D. Kohler, J.-O. Reinhard, M. Sackmann, C. Moser, A. Sek, G. Jacobs, M. Zeitz, et al. Low Sensitivity of the ki-ras Polymerase Chain Reaction for Diagnosing Pancreatic Cancer From Pancreatic Juice and Bile: A Multicenter Prospective Trial J. Clin. Oncol., November 1, 2002; 20(21): 4331 - 4337. [Abstract] [Full Text] [PDF] E. Coustan-Smith, J. Sancho, F. G. Behm, M. L. Hancock, B. I. Razzouk, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, J. T. Sandlund, C.-H. Pui, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood, June 17, 2002; 100(1): 52 - 58. [Abstract] [Full Text] [PDF] M. N. Dworzak, G. Froschl, D. Printz, G. Mann, U. Potschger, N. Muhlegger, G. Fritsch, and H. Gadner Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood, March 15, 2002; 99(6): 1952 - 1958. [Abstract] [Full Text] [PDF] C. Nyvold, H. O. Madsen, L. P. Ryder, J. Seyfarth, A. Svejgaard, N. Clausen, F. Wesenberg, O. G. Jonsson, E. Forestier, and K. Schmiegelow Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome Blood, February 15, 2002; 99(4): 1253 - 1258. [Abstract] [Full Text] [PDF] D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF] J. F. San Miguel, M. B. Vidriales, C. Lopez-Berges, J. Diaz-Mediavilla, N. Gutierrez, C. Canizo, F. Ramos, M. J. Calmuntia, J. J. Perez, M. Gonzalez, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood, September 15, 2001; 98(6): 1746 - 1751. [Abstract] [Full Text] [PDF] A. M. Ford, K. Fasching, E. R. Panzer-Grumayer, M. Koenig, O. A. Haas, and M. F. Greaves Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes Blood, August 1, 2001; 98(3): 558 - 564. [Abstract] [Full Text] [PDF] F. G. Blankenberg, L. Naumovski, J. F. Tait, A. M. Post, and H. W. Strauss Imaging Cyclophosphamide-Induced Intramedullary Apoptosis in Rats Using 99mTc-Radiolabeled Annexin V J. Nucl. Med., February 1, 2001; 42(2): 309 - 316. [Abstract] [Full Text] V. de Haas, W. B. Breunis, O. J. Verhagen, H. van den Berg, and C. E. van der Schoot Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse Blood, August 15, 2000; 96(4): 1619 - 1620. [Full Text] [PDF] This Article Abstract Full Text (PDF) Erratum (v95,p3010) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Panzer-Grümayer, E. R. Articles by Gadner, H. Search for Related Content PubMed PubMed Citation Articles by Panzer-Grümayer, E. R. Articles by Gadner, H. Related Collections Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020